QR Code

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial

Abstract Background High dose vasopressors portend poor outcome in vasodilatory shock. We aimed to evaluate the impact of baseline vasopressor dose on outcomes in patients treated with angiotensin II (AT II). Methods Exploratory post-hoc analysis of the Angiotensin II for the Treatment of High-Outpu...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Patrick M. Wieruszewski, Rinaldo Bellomo, Laurence W. Busse, Kealy R. Ham, Alexander Zarbock, Ashish K. Khanna, Adam M. Deane, Marlies Ostermann, Richard G. Wunderink, David W. Boldt, Stew Kroll, Chuck R. Greenfeld, Tony Hodges, Jonathan H. Chow, the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMC 2023-05-01
Rangatū:Critical Care
Ngā marau:
Angiotensin
Shock
Vasopressor
Catecholamine
Multimodal
Outcomes
Urunga tuihono:https://doi.org/10.1186/s13054-023-04446-1
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite